Feature article: Automation solutions for single-use bioreactors

10. January 2023 by Andreas Pompenig Automation, Biotech, Feature article, Single Use Technology

Integrating Single-Use Systems: ZETA's Automation Expertise

As a leading supplier of customized automation solutions for biopharmaceutical production processes, ZETA seamlessly integrates single-use systems into new or existing automation environments. A landmark project for a major international pharmaceutical company was the starting point for a series of follow-up projects in Switzerland and Germany.

Highest customer satisfaction

The original fast-track project involved the integration and automation of four single-use bioreactors supplied by Cytiva. It included the engineering, manufacturing, and installation of a stainless-steel work platform with utility supply piping for the clean rooms. The customer was highly satisfied and contracted ZETA to supply a second production line.

Integrating Single-Use Systems: ZETA's Automation Expertise.

 

Find out more about our innovative solutions and optimizations in the follow-up projects!

Close

ZETA Blog

Whitepaper Download

Contact Maximilian van de Graaf - Head of Sales Automation
Contact: Maximilian van de Graaf
Head of Sales Automation

Our expert is looking forward
to hearing from you!

Related Posts

Expert Interview: Thomas Engelmaier
Feature Article: Unlocking the Potential of Data-Driven Maintenance
How does the geometry of impeller blades affect the process?
Expert Interview: Roland Maichin
Video: ZETA magnetic agitators for retrofitting
White Paper: Advancements in the field of high-shear mixers
Close

ZETA Blog

Erhalten Sie interessante Themen aus dem Blog als Newsletter!

The digital assistant from ZETA.
The ZETA
Digital Assistant
  • Last
    search queries
  • Last
    webinars
  • Last
    blog posts
The digital assistant from ZETA.
Your ZETA Digital Assistant

Welcome back!

Recently viewed

No results

You have no results yet.

Maybe also interesting

No results

You have no results yet.